Nephrology

Global analysis links elevated BMI and low physical activity to rising hypertension-related chronic kidney disease burden, with deaths projected to increase through 2050.

The FDA has extended its review of the sNDA, delaying the previous January 13, 2026, PDUFA date, to April 13, 2026.

A new national database study suggests malnutrition reverses the obesity survival benefit in hospitalized ESKD patients undergoing dialysis

In a multicenter analysis, ZEBRA, an AI-assisted pathology tool, showed high sensitivity and specificity for detecting Fabry nephropathy in renal biopsies.

A retrospective analysis links low pretransplant exercise tolerance with reduced skeletal muscle recovery and persistent sarcopenia risk after living donor kidney transplantation in CKD.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and other regulatory updates, in this week’s essential news roundup.

A prospective study reports an association between diabetes mellitus and anuria with high post-void residual post-transplantation.

According to new research, investigators project a rising chronic kidney disease burden in young adults and a declining incidence in children by 2050.

A retrospective cohort analysis reports data on a two-sided relationship between depression diagnosis and chronic kidney disease progression.

Quarter 4 2025 showed robust advancements in the nephrology field, including FDA news, trial updates, and featured content.

An age-based observational study in glomerular disease suggests different rates of disease progression and remission in young adults compared to adult and pediatric patients.

The FDA grants priority review of Vera Therapeutics’s Biologics License Application for the B-cell modulating, atacicept, in IgAN.

Retrospective data suggest serum creatinine trajectories might predict 28-day mortality in acute kidney injury on chronic kidney disease.

A cross-sectional study in CKD suggests patients undergoing hemodialysis have increased social frailty and depression compared to transplant recipients.

The updated guideline offers recommendations for RBC transfusions and iron management, while continuing to prioritize patient-centered care.

A qualitative descriptive study of pediatric kidney transplant recipients and caregivers highlights a need for standardized educational materials and treatment information.

New research in patients with end-stage kidney disease suggests an association between neighborhood advantage and access to transplants and waitlists.

In December 2025, intervention strategies, dialysis modalities, and kidney transplantation data provided insight to improve renal care for clinicians.

C3G treatment advances in 2025 with FDA approvals of iptacopan and pegcetacoplan, offering disease-modifying options

IgA nephropathy advanced in 2025 with FDA approvals, positive phase 3 trials, and growing disease-modifying therapies

In 2025, FDA approvals, pivotal trials, and emerging therapies shifted nephrology care toward precision and mechanism-driven kidney medicine.

The FDA has approved an sNDA for the FUROSCIX On-body Infusor in pediatric patients and accepted another for the FUROSCIX ReadyFlow Autoinjector.

A multinational survey suggests even slowly progressing C3G and IC-MPGN substantially affect patients, caregivers, and healthcare systems.

Findings from a retrospective observational cohort study indicate podometrics may inform a less invasive treatment approach in IgA nephropathy (IgAN).

A multi-state cross-sectional analysis linked chronic kidney disease with increased COVID-19 hospitalizations, indicating more severe disease outcomes